


Curriculum Vitae

Name	Do-Youn, Oh	
Current Position & Affiliation	Professor, Division of Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea	
Country	Korea	

Educational Background

- Mar. 1984-Feb. 1987 Sung-San Junior High School, Seoul, Korea. With honor
- Mar. 1987-Feb. 1990 Ewha Women’s High School, Seoul, Korea. With honor
- Mar. 1991-Feb. 1993 Premedical School, Seoul National University, Seoul, Korea
- Mar. 1993-Feb. 1997 College of Medicine, Seoul National University, Seoul, Korea
With honor and scholarship Graduated first on the list
- Mar. 2000-Feb. 2002 Course of Degree of Master in Medicine (Internal Medicine), Seoul National University College of Medicine, Seoul, Korea
- Mar. 2002-Feb. 2004 Course of Doctor of Philosophy in Medicine (Internal Medicine), Seoul National University College of Medicine, Seoul, Korea

Professional Experience

- Mar. 1997-Feb. 1998 Internship course, Seoul National University Hospital, Seoul, Korea
- Mar. 1998- Feb. 2002 Residency course at Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- Mar. 2002- Feb. 2003 Fellowship of Hematology/Medical Oncology, Seoul National University Hospital, Seoul, Korea
- Mar. 2003- Feb. 2006 Faculty member of Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Boramae Hospital, Seoul, Korea

- Mar. 2006-Feb. 2012 Assistant Professor of Division of Medical Oncology,
Department of Internal Medicine,
Seoul National University Hospital, Seoul, Korea
- Mar. 2012-Aug 2016 Associate Professor of Division of Medical Oncology,
Department of Internal Medicine,
Seoul National University Hospital, Seoul, Korea
- Sep 2016- Now Professor, Division of Medical Oncology,
Department of Internal Medicine,
Seoul National University College of Medicine
- Sep. 2011-Aug. 2012 Visiting Assistant Professor
Department of Systems Biology,
MD Anderson Cancer Center, Houston, TX, USA.

Main Scientific Publications

Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. *Nat Rev Clin Oncol.* 2020 Jan;17(1):33-48

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, **Oh DY**, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med.* 2019 Jul 25;381(4):317-327.

O'Reilly EM, **Oh DY**, Dhani N, Renouf DJ, Lee MA, Sun W, Fisher G, Hezel A, Chang SC, Vlahovic G, Takahashi O, Yang Y, Fitts D, Philip PA. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. *JAMA Oncol.* 2019 Jul 18.

Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, **Oh DY**, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, Chemotherapy-Refractory Cholangiocarcinoma (ClarIDHy): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. *Lancet Oncol.* 2020 May 13;S1470-2045(20)30157-1

Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, **Oh DY**, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A. Pemigatinib for Previously

Treated, Locally Advanced or Metastatic Cholangiocarcinoma: A Multicentre, Open-Label, Phase 2 Study. *Lancet Oncol.* 2020 May;21(5):671-684.

Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, **Oh DY**, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T; POLO Investigators. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. *Ann Oncol.* 2019 Dec 1;30(12):1959-1968.

Kim JW, Lee KH, Kim JW, Suh KJ, Nam AR, Bang JH, Bang YJ, **Oh DY**. Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. *Br J Cancer.* 2019 Aug;121(4):332-339

Jin MH, **Oh DY**. ATM in DNA repair in cancer. *Pharmacol Ther.* 2019 Jul 9:107391. doi: 10.1016/j.pharmthera.2019.07.002. [Epub ahead of print]

Yoo SH, Kang SY, Cheon GJ, **Oh DY**, Bang YJ. Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity during Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study. *J Nucl Med.* 2019 Jun 14. pii: jnumed.119.226407. doi: 10.2967/jnumed.119.226407. [Epub ahead of print]